A strategic financial analysis of iPSC-based manufacturing
vs. autologous models
Author: Astrid Van Damme, PhD – Head of Project Management
Highlights
- Industrialized iPSC manufacturing is emerging as the decisive factor in making cell therapies scalable, affordable, and commercially viable.
- Standardized, off‑the‑shelf production models remove the barriers of autologous manufacturing and enable global deployment.
- Real‑world analysis: based on the Echo™ NK platform, the study quantifies up to a 95% reduction in COGS through industrialized iPSC manufacturing.
- Batch yield and facility utilization are identified as the dominant economic levers determining long‑term sustainability and margin expansion.
- The cost structure shifts from labor‑driven to materials‑driven, enabling predictable, reproducible, and scalable economics.
- Standardization delivers not only efficiency but also market access and reimbursement viability—turning scalability into a strategic advantage.
Access the full paper
including detailed cost modeling, Echo™‑NK case data, and economic benchmarks.
Executive summary
To validate this logic, Cellistic’s Echo™‑NK platform was developed as an end‑to‑end GMP manufacturing system for iPSC‑derived NK cell therapies. Analysis demonstrates a shift from labor‑driven to materials‑driven COGS, with overall economics most sensitive to batch yield and facility utilization.
For this analysis, Cellistic drew on data from Echo™‑NK, one of its end‑to‑end GMP manufacturing platforms for iPSC‑derived NK cell therapies. This real‑world use case illustrates how industrialized iPSC production drives a shift from labor‑intensive to materials‑driven COGS, with economics most influenced by batch yield and facility utilization.